Clinical trial shows wrist device significantly reduces tics in Tourette syndrome

Saturday, 11 March 2023

The results of the clinical trial of a new wrist device designed to help control the symptoms of Tourette syndrome have shown it significantly reduces the severity and frequency of tics.

The prototype wrist device, which was recently tried out by Lewis Capaldi, delivers electrical pulses to reduce the amount and severity of tics experienced by individuals with Tourette’s and was trialed by 121 people across the UK. The results have been announced in MedRxive.

The device has been developed by scientists at the University of Nottingham and spin-out company Neurotherapuetics Ltd who have recently secured £1m in additional funding to commercialise the ‘Neupulse’ device with the aim of having a device and App available within the next 3 years.

Tourette Syndrome (TS) is a neurodevelopmental condition that is usually diagnosed between the ages of eight and 12. It causes involuntary sounds and movements called tics. Tics are repetitive, stereotyped movements and vocalisations that occur in bouts, typically many times in a single day, and are often preceded by a strong urge-to-tic, referred to as a premonitory urge (PU).

Previous research by scientists from the University of Nottingham’s School of Psychology and School of Medicine used repetitive trains of electrical stimulation to the median nerve (MNS) at the wrist to entrain rhythmic electrical brain activity - known as brain oscillations - associated with the suppression of movements. They found that rhythmic MNS substantially reduces tic frequency and tic intensity, and remove the urge-to-tic, in individuals with TS.

Trial participants used the device at home at a similar time each day for 15 mins for a period of one month. A subset of people were also videoed each day. Each week participants gave feedback on their experience.

The results of the trial revealed that people who received active stimulation experienced a significant reduction in the severity and frequency of their tics. On average, they saw a reduction in tic frequency of more than 25% while they received stimulation.

After using the device for 4 weeks, people who received active stimulation experienced a reduction in their tic severity of more than 35%. In total, 59% of the people who received active stimulation experienced a reduction in tic severity of at least 25% compared to baseline.

13-year-old Mylo was one of the participants in the trial. His parents noticed unusual symptoms when he was a toddler, but he wasn’t diagnosed until he was 10 after his tics became more noticeable. He said: “The device was easy to use - you strap it on like a watch and press a button to start it. You have to make sure the pads are on the back properly otherwise it might hurt a tiny bit. When the stimulation occurs it feels a bit like a fizzing on my wrist and forearm, not painful just a bit different.

The device definitely helped my tics. I still did the occasional tic when it was on but the need to do it was a lot less. I definitely want this device when it is available. I think it can help people with Tourette's in different ways. For me, I would use it if I was going to the cinema or the theatre - places where you sometimes have to be quiet or still so you don't disturb people. Tourette's can be really exhausting sometimes, like when you have a tic attack and can't get a break from it - this device could really help with that. I think different people would benefit in different ways - because Tourette's can vary quite a lot. I don't think I would use it all day, just when I felt I especially needed it.”

Mylo’s mum Alex added: “I feel this device could be a great safety net for us. I don't know how Mylo's Tourette's will progress as he gets older, but knowing there is something out there that can help if he wants it makes me feel so much better. I would also say that the device might not be for everyone - if you are accepting of your tics and they don't impact your life you might not want or need it, but for those people that really struggle I believe it will make a significant impact with daily challenges. We feel really lucky to have taken part in the trial.”

Though the Neupulse device is still early in development, the results of this UK-wide double-blind clinical trial have been extremely encouraging. This device has the potential to dramatically improve the lives of those with Tourette syndrome, who often face challenges managing their tics, by providing increased control over their tics on demand.
Professor Stephen Jackson from the University of Nottingham and Chief Scientific Officer at Neurotherapeutics Ltd

Dr. Barbara Morera Maiquez, Chief Research Officer at Neurotherapeutics Ltd managed the trial, she commented: “The results of this trial mark an exciting step towards an effective, non-invasive treatment for Tourette syndrome that can be used at home. We are now focused on using the knowledge from the trial to develop a commercial device that can be made available to people with Tourette’s.”

Dr. Barbara Morera Maiquez, Chief Research Officer at Neurotherapeutics Ltd who managed the trial

The research has been funded by the charity Tourettes Action, NIHR Nottingham Biomedical Research Centre and Neurotherapeutics Ltd.

The results of the trial are extremely promising. Many with Tourette’s suffer with pain caused by the repetitive nature of their tics and often find it hard to get any respite from this. The device could provide them with a useful self-managing treatment to help them better manage and control their tics, ultimately giving them a break from the tic pain cycle. It could potential improve the lives of so many people.
Emma McNally, Chief Executive Officer of Tourettes Action

Story credits

More information is available from Professor Stephen Jackson on

Jane Icke - Media Relations Manager Science
Phone: 0115 7486462

Notes to editors:

About the University of Nottingham

Ranked 32 in Europe and 16th in the UK by the QS World University Rankings: Europe 2024, the University of Nottingham is a founding member of the Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.

Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 – the third time it has been given the honour since 2018 – and by the Daily Mail University Guide 2024.

The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.

The university is a major employer and industry partner - locally and globally - and our graduates are the second most targeted by the UK's top employers, according to The Graduate Market in 2022 report by High Fliers Research.

We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.

More news…

Media Relations - External Relations

The University of Nottingham
YANG Fujia Building
Jubilee Campus
Wollaton Road
Nottingham, NG8 1BB

telephone: +44 (0) 115 951 5798